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Abstract
Purpose To guide early stage breast cancer patients to choose between breast conserving surgery (BCS) and mastectomy 
(MST) considering the predicted cosmetic result and quality of life (QoL).
Methods A decision model was built to compare QoL after BCS and MST. Treatment could result in BCS with good cos-
mesis, BCS with poor cosmesis, MST only, and MST with breast reconstruction. QoL for these treatment outcomes were 
obtained from a previous study and the literature and translated into EuroQoL-5D derived utilities. Chance of good cosmesis 
after BCS was predicted based on tumor location and tumor/breast volume ratio. The decision model determined whether 
the expected QoL was superior after BCS or MST based on chance of good cosmesis.
Results The mean utility for the treatments such as BCS with good cosmesis, BCS with poor cosmesis, MST only, and MST 
with breast reconstruction were 0.908, 0.843, 0.859, and 0.876, respectively. BCS resulted in superior QoL compared to 
MST in patients with a chance of good cosmesis above 36%. This 36% threshold is reached in case the tumor is located in 
the upper lateral, lower lateral, upper medial, lower medial, and central quadrant of the breast with a tumor/breast volume 
ratio below 21.6, 4.1, 15.1, 3.2, and 14.7, respectively.
Conclusions BCS results in superior QoL in patients with tumors in the upper breast quadrants or centrally and a tumor/
breast volume ratio below 15. MST results in superior QoL in patients with tumors in the lower breast quadrants and a tumor/
breast volume ratio above 4.
Keywords Treatment decision making · Breast cancer surgery · Breast conserving surgery · Mastectomy · Breast 
reconstruction · Cosmetic result
Introduction
Early stage breast cancer patients and their surgeons are con-
fronted with the complex decision between breast conserv-
ing surgery (BCS) with radiotherapy or mastectomy (MST) 
with or without breast reconstruction. Both have similar 
overall survival [1–3]. In the absence of an oncological 
contraindication for BCS, the treatment choice is a matter 
of expected cosmetic result that influences quality of life 
(QoL) [4, 5]. The surgeon and patient discuss the expected 
cosmetic result of both BCS and MST, but preoperative pre-
diction of the cosmetic result is typically based on informal 
assessment by the surgeon. An objective decision aid taking 
cosmesis and QoL into consideration does not exist.
It is generally believed that the benefit of BCS over MST 
depends on the cosmetic result after BCS. Good cosmesis 
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after BCS has shown to yield a substantial QoL benefit over 
poor cosmesis [4]. Therefore, it can be hypothesized that 
BCS is preferable when the chance of a good cosmetic result 
is high, but MST (with or without breast reconstruction) is 
preferable when BCS is unlikely to have a good cosmetic 
result. We have previously demonstrated that a good cos-
metic result after BCS can be predicted preoperatively by 
tumor volume/breast volume ratio (TV/BV ratio) and tumor 
location [6]. It remains unknown above what specific chance 
of good cosmetic result, BCS results in higher QoL over 
MST. If BCS is already performed for a low chance of good 
cosmesis, too many patients receive BCS increasing the inci-
dence of poor cosmesis and reducing QoL. If BCS is only 
performed in those patients where good cosmesis is very 
likely and MST is performed otherwise, too many patients 
receive MST reducing QoL.
The aim was to guide decision making for patients with 
early stage breast cancer using a decision model that consid-
ers both predicted cosmetic result and QoL after BCS and 
MST. The treatment threshold—when to treat with BCS or 
MST—for optimal QoL is calculated. In clinical practice, 
this decision model could inform the treatment decision by 
weighing QoL of each treatment option.
Methods
Study population
Data from a study population of 69 patients previously 
described in more detail formed the basis for the current 
analysis [6]. During first year, all consecutive patients who 
came for follow-up visit at the outpatient clinic at the Eras-
mus MC Cancer Institute were asked to participate. Eligibil-
ity criteria included: Females above 18 years old with BCS 
and adjuvant radiotherapy between 2007 and 2012 for an 
invasive breast cancer with a preoperative MRI available. 
Preoperative MRI was an inclusion criterion to allow accu-
rate breast volume measurements. BCS was performed using 
basic oncoplastic techniques, but no volume replacement 
techniques or therapeutic reduction mammoplasty. Patients 
with MST were not eligible since at first we only aimed 
to build a prediction model for cosmetic result after BCS. 
Informed consent was obtained from all participants.
The study population from Jagsi et al. consisted of woman 
aged between 20 and 79 years with stage 0–III breast cancer 
diagnosed between 2005 and 2007 and treated with MST 
only (n = 263) or MST with reconstruction (both implant 
and autologous, both immediate and delayed) (n = 222) 
from the Los Angeles and Detroit population based Sur-
veillance, Epidemiology, and End Results registries. These 
were the patients that responded to a survey including QoL 
questionnaire at 9 months after diagnosis and approximately 
4 years later constituting a 73 and 68% response rate [7]. 
Patient characteristics of both study populations are shown 
in Table 1.
Tumor volume/breast volume ratio and tumor 
location
The preoperative MRI datasets were transferred to a four-
walled CAVE™-like virtual reality system (i.e., the I-Space), 
at the department of Bioinformatics, Erasmus MC. The vol-
ume rendering application creates an interactive ‘hologram’ 
of the MRI and reliably performs volume measurements 
based on greyscale differences [8]. Interclass and intraclass 
correlation coefficients for tumor and breast volumes all 
exceeded 0.95 [6]. Tumor volume/breast volume ratio (TV/
BV ratio) was calculated by dividing the tumor volume in 
 cm3 by the breast volume in  cm3 and multiplied by 1000. 
Details about the TV/BV ratio were published elsewhere 
[6]. The tumor location was determined by the radiologist 
and designated to one of the four quadrants of the breast or 
a central position.
Table 1  Patient and treatment characteristics of the two study popula-
tions from whom the QoL values were translated into EQ-5D derived 
utilities
a Our study population for the health states BCS with good cosmetic 
result and BCS with poor cosmetic result
b Study population from Jagsi et  al. [7] for the health states Mastec-
tomy only and Mastectomy with breast reconstruction
BCSa (n = 69) Mastectomyb 
(n = 485)
P value
Age (years) 0.072
 ≤ 45 8 (11.6) 99 (20.4)
 46–55 28 (40.6) 140 (28.9)
 ≥ 56 33 (47.8) 246 (50.7)
Stage < 0.001
 0 – 99 (20.4)
 I 45 (65.2) 133 (27.4)
 II 20 (29.0) 164 (33.8)
 III 1 (1.0) 87 (17.9)
 Missing 3 (4.3) 2 (0.4)
Radiotherapy < 0.001
 Yes 69 (100) 144 (29.7)
 No – 322 (66.4)
 Missing – 19 (3.9)
Chemotherapy 0.054
 Yes 31 (44.9) 278 (57.3)
 No 38 (55.1) 198 (40.8)
 Missing – 9 (1.9)
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Cosmetic result evaluation
Cosmetic result was determined by panel assessment of 
post-radiotherapy photographs. The panel consisted of a 
plastic surgeon, general surgeon, radiotherapist, general 
practitioner, layperson, and breast cancer patient. They each 
scored the four photographs taken by a professional medical 
photographer in a standardized manner. The self-developed 
‘Erasmus MC Panel questionnaire’ (Online Resource 1) 
consisting of eleven items was scored on a four-point scale 
(0 = excellent, 1 = good, 2 = moderate, 3 = poor) [6]. If the 
average score of all items and panel members was below or 
equal to 1.5, it was categorized as a good cosmetic result. In 
case the average score was above 1.5, it was categorized as 
a poor cosmetic result.
Cosmetic result prediction model
In the study population of 69 BCS patients, a preoperative 
prediction model for good cosmetic result after BCS was 
built [6]. It included the two independent and statistically 
significant predictors, namely TV/BV ratio (on a continuous 
scale) and tumor location (categorical variable with upper 
lateral (reference), upper medial, lower lateral, lower medial 
quadrant, and central). The following parameters were not 
independently associated with cosmetic result and therefore 
not included in the prediction model: age, tumor diameter, 
excision volume, presence of adjacent DCIS, use of re-exci-
sion, and time of follow-up. Specimen weight was excluded 
from the analyses, because it was not preoperatively avail-
able. The analysis for cosmetic result predictors can be found 
in Online Resource 2.
The prediction model result (R) is the chance of a good 
cosmetic result after BCS. The original formula of R is 
shown in Online Resource 3, equation 1. The prediction 
model inherently has true positives (i.e., good cosmesis is 
predicted which is true), false positives (i.e., good cosmesis 
is predicted but not true), true negatives (i.e., poor cosmesis 
is predicted which is true) and false negatives (i.e., poor cos-
mesis is predicted but not true) (Fig. 1). However, a thresh-
old at which BCS is preferred— at what chance of good 
cosmesis it is better to perform BCS rather than MST—is 
unknown. The threshold at which BCS is preferred can be 
established by modeling the harms and benefits in QoL for 
each treatment approach.
Treatment decision tree
A treatment decision tree was developed to model the treat-
ment consequences of the prediction model and the predic-
tion model inherent uncertainty (Fig. 2). Patients entered 
the tree having the diagnosis of invasive breast cancer stage 
I–IIIA opting for BCS. Each endpoint in the decision tree 
represents a ‘health state’, namely the health states BCS with 
good cosmesis (i.e., true positive result), BCS with poor 
cosmesis (i.e., false positive result), mastectomy only, and 
mastectomy with breast reconstruction (i.e., both a negative 
result). Note that after a MST, it is impossible to distinguish 
between a true negative result (i.e., poor cosmesis if BCS 
had been performed) and a false negative result (i.e., good 
cosmesis if BCS had been performed). We assumed good 
cosmesis after BCS is preferred over MST (± reconstruc-
tion) and MST (± reconstruction) is preferred over poor 
cosmesis after BCS. It was also assumed that QoL after 
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Fig. 1  Smooth ROC curve and equation of the prediction model for 
the chance of a good cosmetic result after breast conserving surgery 
(BCS). The prediction model combines the individual patient’s tumor 
volume/breast volume ratio and location of the tumor in the breast. 
Area under the operating characteristic curve (AUC) was 0.83 (95% 
CI 0.71–0.94)
p(good/R) >  
threshold 
Patient with early stage breast cancer 
BCS 
Mastectomy 
Good cosmetic result 
Poor cosmetic result 
QoL (BCS,good) 
QoL (BCS,poor) 
p(good/R) < 
threshold 
p(good/R) 
1-p(good/R) 
No breast reconstruction 
Breast reconstruction QoL (Mastectomy with 
breast recontruction) 
1-p(reconstruction/R) 
p(reconstruction/R) 
QoL (Mastectomy only) 
Fig. 2  Treatment decision tree in early staged breast cancer patients 
comparing BCS and MST. The model determines when BCS is 
superior to MST depending on the chance of a good cosmetic result 
and the postoperative QoL. The chance of a good cosmetic result is 
based on the individual patient’s tumor volume/breast volume ratio 
and tumor location which is calculated by our prediction model (R). 
The treatment threshold for the chance of a good cosmetic result is 
reached when the QoL of BCS and MST are equal; BCS is preferred 
for values above the threshold and MST is preferred for values below 
the threshold. BCS breast conserving surgery, p probability, R result 
of prediction model for cosmetic result after BCS, QoL quality of life
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BCS is related to the cosmetic result. The probability of the 
health state BCS with good cosmesis equaled the prediction 
model probability for good cosmesis. The opposite from this 
equaled the probability for BCS with poor cosmesis. The 
probability of breast reconstruction was estimated from the 
most recent study with breast reconstruction rate as their 
primary outcome [9]. The opposite of this equaled the prob-
ability for MST only.
Quality of life
The primary outcome of each health state in the decision 
tree was a long-term QoL weight from the patient’s perspec-
tive. Since life expectancy is equivalent for MST and BCS 
[1–3], the primary outcome measure QoL was used instead 
of the quality-adjusted life-years. QoL was defined as a util-
ity, which is a single index-based value between 0 and 1 
that enables assessing the effects of interventions on health-
related quality of life. In contrast to most patient-reported 
outcome measures, the EuroQoL 5D (EQ-5D) offers utilities 
[10]. Making use of time trade-off experiments, preference 
weights (tariffs) have been determined, and each health state 
of the EQ-5D can be assigned an index score. Freedman 
et al. describes the largest population (n = 1050) with EQ-5D 
derived utilities at 5 years after BCS in the literature [11]. 
However, no distinction was made in cosmetic result. To 
obtain a robust utility for good and poor cosmesis, from 
our study population the gain and loss in utility for a good 
and poor cosmesis was added to the mean utility after BCS 
from Freedman et al. (analysis are shown in Online Resource 
4). The EORTC QLQ-C30 values from our study popula-
tion were converted into EQ-5D compatible utilities making 
use of the ‘map’ from Crott et al. (ordinary least squares 
regression model 3) [12, 13]. For the health states involving 
MST, the most recent and representative QoL values from 
the literature by Jagsi et al. were used [7]. The FACT-G 
QoL values from the study population of Jagsi et al. were 
converted into EQ-5D compatible utilities making use of 
the map from Teckle et al. (ordinary least squares regression 
model 2) [14]. All raw QoL values and equations for conver-
sion to EQ-5D utilities can be found in Online Resource 4.
Treatment threshold
The definition of a treatment (treat—do not treat) threshold 
is the probability of disease at which the expected value of 
treatment and no treatment are equal [15]. When applied 
to the current study, the treatment threshold—to perform 
BCS or not—was defined by the chance of good cosmetic 
result after BCS at which the QoL after BCS and the QoL 
after MST (± breast reconstruction) was equal. The thresh-
old can be determined by direct comparison of the benefits 
and harms of BCS. The benefit is defined as the gain in QoL 
from living with a good cosmetic result after BCS instead of 
a MST (± breast reconstruction) (Online Resource 3, equa-
tion 2A). The harm is defined by the loss in QoL from living 
with a poor cosmetic result after BCS instead of a MST (± 
breast reconstruction) (Online Resource 3, equation 2B).
BCS should be performed when the chance of good cos-
mesis after BCS exceeds the harm to benefit ratio as pre-
sented in the Online Resource 3, equation 3A. Rewriting 
this expression as probability and substituting equation 2A, 
B leads to equation 3B, C [16]. The treatment threshold was 
determined by inserting the utilities in the equation.
Data analysis
The prediction model for good cosmetic result after BCS 
developed in our study population consists of (1) regression 
coefficients representing the influence of the variables TV/
BV ratio and tumor location on the (log odds of the) proba-
bility of good cosmesis and (2) an intercept representing the 
prior probability of good cosmesis in the study population. 
No random effects were included in the prediction model. 
The models predictive ability was estimated by area under 
the operating characteristic curve (AUC). However, the 
prior probability was assumed to be higher than the actual 
prevalence of good cosmesis since women with a false nega-
tive prediction model outcome (i.e., poor cosmesis is pre-
dicted but not true) underwent MST and therefore, were not 
included in the study population; even though a good cos-
metic result was expected if BCS had been performed. The 
number of false negatives is unknown. Therefore, a prior 
probability slightly larger (2%) than the actual prevalence 
in the study population was chosen to correct for these false 
negatives and the intercept of the updated prediction model 
was recalculated (Online Resource 3, equation 4 and Fig. 1).
A probabilistic sensitivity analysis (PSA) was performed 
to evaluate the joint effect of uncertainty about all param-
eters in the model [17]. Parameter uncertainty was expressed 
by beta probability distributions on the interval [0, 1]. There-
after, 10,000 times random values from the distributions of 
all variables were drawn and the model was recalculated 
for each set (sample) of values using an average patient, 
resulting in a probability distribution of the expected out-
come (i.e., average expected utility for BCS and MST). The 
average patient was determined by calculating the study 
population mean for each parameter included in the pre-
diction model. Subsequently, the expected benefit in util-
ity per patient in the absence of parameter uncertainty (i.e., 
expected value of perfect information, EVPI) was deter-
mined. In each sample, the opportunity loss was defined as 
the difference in utility between the maximum expected ben-
efit of that sample (BCS or MST) and the sample’s expected 
benefit of the baseline optimal treatment (BCS) [17]. P 
values were derived from two-tailed tests and P < 0.05 was 
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considered significant. Microsoft Excel 2010 and IBM SPSS 
Statistics version 22 were used for all analyses. There was 
no funding support for this study.
Results
Tumor volume/breast volume ratio and tumor 
location
In the 69 breast cancer patients with preoperative MRI and 
treated by BCS, the median TV/BV ratio was 2.47 (IQR 
1.25–5.54). Thirty-three (47.8%) tumors were located in 
the upper lateral quadrant, 14 (20.3%) tumors in the upper 
medial quadrant, 13 (18.8%) tumors in the lower lateral 
quadrant, 3 (4.3%) tumors in the lower medial quadrant, and 
6 (8.7%) tumors in a central position.
Chance of good cosmetic result
Median time between surgery and cosmetic result assess-
ment was 33 months (interquartile range 18–48). The panel 
evaluation of cosmetic result resulted in 49/69 (71.0%) 
patients with good cosmesis (i.e., Erasmus MC Panel 
score ≤ 1.5) and 20/69 (29.0%) patients with poor cosmesis 
(i.e. , Erasmus MC Panel score > 1.5). The median chance 
of good cosmetic result from the prediction model was 0.84 
(interquartile range 0.45–0.92). The formula of the predic-
tion model is depicted in Fig. 1. The prediction model had an 
area under the operating characteristic curve (AUC) of 0.827 
(95% CI 0.71–0.94) meaning that in 82.7% of the cases, 
it correctly discriminated between poor and good cosme-
sis (Fig. 1). Other patient and treatment characteristics are 
shown in Table 1. Four oncological surgeons almost exclu-
sively performing breast surgery operated 61/69 (88.4%) of 
the patients and 8/69 (11.6%) of the patients were operated 
by general oncological surgeons.
Quality of life
Of the 69 patients with BCS included, 61 (88.4%) responded 
to the EORTC QLQ-C30 questionnaire to evaluate their QoL 
at a median of 38 months (interquartile range 31–54) after 
surgery. From the respondents, 44 had good cosmetic result 
and 17 had poor cosmetic result. Utilities are presented in 
Table 2 and their calculations are shown in Online Resource 
4. The mean utility for poor cosmesis and good cosmesis 
were not statistically significantly different (P = 0.055). After 
linear regression analysis, QoL was not statistically signifi-
cantly associated with increasing age (coefficient 0.002 95% 
CI − 0.002 to 0.006), higher breast cancer stage (coefficient 
− 0.008 95% CI − 0.070 to 0.054), and adjuvant chemother-
apy (coefficient − 0.018 95% CI − 0.080 to 0.044).
Jagsi et al. included 263 patients with MST only and 222 
patients with MST plus reconstruction (see patient char-
acteristics Table 1) who completed the FACT-G that was 
measured at a mean of 50 months (standard deviation 5) 
after diagnosis (see utilities in Table 2 and calculations in 
Online Resource 4).
When to treat with BCS or MST for superior QoL
The benefit in utility from performing BCS with a good 
cosmetic result rather than a MST (± reconstruction) was: 
0.908 − 0.866 = 0.042 (Table 2) (Online Resource 3, equa-
tion 2A). The harm in utility from performing BCS with a 
poor cosmetic result rather than a MST (± reconstruction) 
was: 0.866 − 0.843 = 0.023 (Table 2) (Online Resource 3, 
equation 2B). BCS should be performed if the chance of a 
good cosmetic result exceeds 35.8% (Online Resource 3, 
equation 6) (Fig. 3). For application in clinical practice, the 
following decision rule can be used. BCS is preferred for 
an upper lateral, lower lateral, upper medial, lower medial, 
Table 2  Utilities
BCS, good cosmetic result 0.908
BCS, poor cosmetic result 0.843
Mastectomy only 0.859
Mastectomy with breast reconstruction 0.876
Mastectomy (± reconstruction) 0.866
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Fig. 3  Decision graph to determine whether the expected QoL after 
surgery is better with BCS (green zone) or MST (red zone). The deci-
sion is based on the chance of a good cosmetic result. The decision 
model demonstrated that QoL after BCS is superior if the chance 
of a good cosmetic result exceeds 36%. The chance of a good cos-
metic result varies between patients and depends on the location 
of the tumor and the ratio of tumor volume and breast volume. For 
example, a patient with a lower lateral tumor and a volume ratio of 
15 has a low chance of a good cosmetic result after BCS (about 10%) 
and should therefore consider undergoing MST. On the other hand, 
a patient with an upper lateral tumor and the same ratio of 15 has a 
60% chance of a good cosmetic result after BCS (about 60%) and 
should consider BCS. BCS breast conserving surgery, MST mastec-
tomy (with or without breast reconstruction). (Color figure online)
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and central tumor location in case the TV/BV ratio is below 
21.6, 4.1, 15.1, 3.2, and 14.7, respectively (Fig. 3). From all 
9 patients with a chance of good cosmesis below 35.8% (i.e., 
negative result) 8/9 had a TV/BV ratio above 5.0 and 7/9 had 
their tumor located in the lower lateral quadrant.
Figure 4 shows the number of true positives, true nega-
tives, false positives and false negatives when the predic-
tion model is applied to our study population. Nine out of 
69 patients (13.0%) had a chance of good cosmesis below 
35.8% (i.e., negative) and would have been advised against 
BCS had the results of our analysis been available. Of these 
9 patients, 8 indeed had a poor cosmetic result (i.e., true 
negative) and 1 patient was classified as good cosmetic result 
(i.e., false negative). The corresponding negative predictive 
value of the prediction model was 88.9%. The false nega-
tive patient had a chance of good cosmesis of 33.8%, which 
was very close to the threshold. Of the 60 patients with a 
chance of good cosmesis exceeding 35.8% (i.e., positive), 
48 patients indeed had a good cosmetic result (i.e., true posi-
tive) and 12 patients were classified as poor cosmetic result 
(i.e., false positive). The corresponding positive predictive 
value of the prediction model was 80.0%. The false positive 
patients had a chance of good cosmesis ranging between 
39–93%.
Parameter uncertainty
The average patient from our study population had a chance 
of good cosmetic result after BCS of 71%. For example, a 
patient with a tumor of 3.8 cm3 in the upper medial quad-
rant in a breast of 675 cm3 resulted in a TV/BV ratio of 5.6. 
Taken into consideration, the parameter uncertainty of our 
decision model, for this patient on average BCS was the 
treatment with the largest benefit in QoL and was advised 
in 61.9% of the 10,000 samples (see probabilistic sensitivity 
analysis in Online Resource 5). If we reduced our parameter 
uncertainty, the benefit in QoL would be 0.02 per patient 
(see expected value of perfect information analysis in Online 
Resource 5).
Discussion
BCS is the treatment with superior QoL for breast cancer 
patients with a chance on good cosmetic result exceeding 
36%. This 36% threshold is reached in case of an upper lat-
eral, lower lateral, upper medial, lower medial, and central 
tumor location in combination with a tumor/breast volume 
ratio below 21.6, 4.1, 15.1, 3.2, and 14.7, respectively. In 
case of larger tumor/breast volume ratio’s, MST (with or 
without breast reconstruction) will result in higher QoL.
Due to the progress in surgical techniques and improving 
oncological outcomes, QoL and cosmesis have an increas-
ingly prominent role in breast cancer treatment. Incorpo-
rating QoL and cosmesis in a treatment decision model 
comes with challenges due to their subjective entity. Cos-
mesis cannot be captured in clear-cut classifications and a 
(gold) standard for measuring cosmesis after BCS is lacking. 
Consequently, the validity of this decision model depends 
on the methodology of measuring and predicting cosmetic 
result and the definition of good and poor cosmesis. This 
is a weakness of our study since the validity of our defini-
tions and self-developed Erasmus MC Panel questionnaire 
have not been tested extensively. The panel assessment is 
therefore study specific. How to measure cosmetic result 
after BCS is still a matter of debate, however, a multiple-
person panel evaluation remains the most used and recom-
mended [18]. It does come with disadvantages as it remains 
a subjective method with low reproducibility results influ-
enced by the type of observers (experts versus non-experts) 
and the scale used. Consensus increases if the outcome is 
dichotomized. It could be argued that cosmetic result should 
be based on a patient-reported outcome measure (PROM). 
Fig. 4  The predicted cosmetic results of the study population on 
the x-axis are plotted against the cosmetic result as evaluated by the 
panel on the y-axis. The horizontal line is set at a panel evaluation of 
cosmetic result cut-off score of 1.5. Values ≤ 1.5 are defined as good 
cosmesis and values > 1.5 as poor cosmesis. The vertical line is set 
at the treatment threshold of 0.36 resulting from the decision model. 
If the predicted cosmetic result is below the threshold, mastectomy 
(with or without reconstruction) results in the optimal QoL. If the 
predicted cosmetic result is above the threshold, BCS results in the 
optimal QoL. This figure shows the number of true positives (good 
cosmesis after BCS as predicted preoperatively), true negatives (poor 
cosmesis after BCS as predicted preoperatively), false positives (poor 
cosmesis after BCS but preoperative prediction was good), and false 
negatives (good cosmesis after BCS but preoperative prediction was 
poor) when the prediction model is applied to the study population. 
The eight patients operated by an—non breast cancer specific—onco-
logical surgeon were colored in red. (Color figure online)
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However, PROM’s only deliver scores on a continuous scale 
and their predictive ability is low (e.g., TV/BV ratio was not 
associated with patient evaluation of cosmetic result) [6]. 
The more efficient BCCT.core software for cosmetic result 
evaluation might become the future standard, but until today, 
agreement with panel evaluations differs [19, 20]. The 12 
patients with false positive result (i.e., model predicted a 
good cosmetic result but the panel evaluated cosmesis as 
poor) could be explained by the fact that 8 out of 12 patients 
had visible radiotherapy fibrosis or skin color changes and 
retractions around the scar which is not taken into consid-
eration in the predicted cosmetic result. Another explana-
tion could be that 3/12 (25%) of false positive patients were 
operated by a general oncological surgeon (i.e., not breast 
cancer specific surgeon) as compared to 8/69 (12%) of the 
total study population. This suggests that surgeon experi-
ence matters for achieving a good cosmetic result. The lack 
of other significant parameters, like radiotherapy boost, in 
the prediction model for cosmetic result was a disadvantage. 
Yet the model proved to discriminate well between poor and 
good cosmetic result (AUC of 0.83). As far as we know, 
other prediction models for cosmetic result or other deci-
sion models including cosmetic result and/or QoL are not 
available in the literature. Therefore, our models could not 
be compared or tested for external validity.
QoL is a complex and multifactorial outcome that is not 
captured by cosmesis and type of surgery only. For example, 
age, chemotherapy, and fear of recurrence have been shown 
to be associated with QoL [21–23]. However, fear of recur-
rence was not considered here and no significant association 
was seen between QoL and age, stage, or chemotherapy. The 
lack of adjusted utilities for these factors was a drawback. 
Future studies should also address fear of recurrence. The 
mean utility found for poor and good cosmesis after BCS 
were not significantly different (P = 0.055). No sample size 
calculation was performed for this study and it was not pow-
ered to show a significant QoL difference. The nature of 
our tertiary referral university hospital caused a small study 
population for BCS. This had multiple implications, like the 
lack of power to detect QoL differences and large (statisti-
cal) uncertainty of the utilities for BCS. To decrease this 
uncertainty, the mean utility for BCS in general measured by 
EQ-5D in 1050 patients from Freedman et al. was used [11]. 
The results are, however, not directly generalizable beyond 
our study population and need to be validated. Due to the 
small sample size, the results of this study are preliminary. 
Work to validate the results in a larger study is underway.
It was assumed that QoL after BCS would be related 
to the cosmetic result. However, cosmesis was not signifi-
cantly associated with EORTC QLQ C-30 and BR-23 scores, 
although absolute differences were seen [e.g., body image 
score of 87 vs. 73 (0–100) in good versus poor cosmesis, 
P = 0.203] [6]. This could be explained by the fact that all 
the questionnaires are general or disease-specific, not cos-
metic result specific. The assessment of cosmesis after BCS 
by an independent panel, and the lack of a panel assessment 
after MST (with and without breast reconstruction), could 
also explain the lack of association with PROM’s. Studies 
with patients’ cosmetic evaluation, however, were signifi-
cantly associated with QoL [4, 5]. A larger study population 
is needed to draw final conclusions about whether EQ-5D 
is sensitive for breast cancer surgery outcome differences. 
Promising alternatives for future efficiency analysis are the 
recently published EORTC Quality of Life Utility Measure-
Core 10 dimensions (QLU-C10D) [24], EORTC Quality of 
Life for women undergoing breast reconstruction (QLQ-
BRECON26) [25], and the modernized EORTC BR23 mod-
ule that is currently under development.
Another disadvantage was the complexity and use of dif-
ferent sources for generating the utilities. Namely, EORTC 
values with EQ-5D UK tariffs from our study population, 
EQ-5D values with unknown origin of tariffs from Freedman 
et al. and FACT values with EQ-5D US tariffs from Jagsi at 
el. The time of measurement was 38 months after surgery, 60 
months after surgery, and 50 months after diagnosis, respec-
tively. We did not correct for these time differences. Neither 
did we correct for the variety in study population size, but 
the standard deviations in the PSA show that the uncertainty 
for most BCS related parameters is larger when compared to 
the MST-related parameters caused by a smaller study popu-
lation. The mastectomy group had more stage III patients (1 
vs. 18%) who underwent less radiotherapy (100 vs. 30%), 
but this was not unexpected. An alternative for using mul-
tiple sources to define the utilities for each health state was 
not available since, as far as we know, no study has been 
published presenting EQ-5D derived QoL values for the dif-
ferent surgical treatments of breast cancer. We were the first 
to compare utilities between BCS and MST.
Whether the differences in utilities found between the 
treatment options are clinically meaningful can be ques-
tioned. The minimally important difference has been esti-
mated to be 0.08 for UK-based EQ-5D scores and 0.06 for 
US-based EQ-5D scores by Pickard et al [26]. We found a 
difference between good and poor cosmetic result after BCS 
of 0.065. However, Pickard et al. estimated the minimally 
important differences in advanced stage patients with can-
cers from all kinds of primary origin. Our study population 
consists of early stage breast cancer patients that already 
have a high baseline QoL (towards the maximum of one) 
which may impede finding large QoL differences. Other 
studies comparing QoL between treatment options showed 
comparable ranking order of the treatments to our decision 
model [7, 27, 28]. Which is important since our decision 
model assumes BCS with good cosmesis is preferred over 
MST (with or without reconstruction) followed by BCS 
with poor cosmesis. Atisha et al. and Jagsi et al. found that 
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satisfaction with breasts as measured by Breast-Q question-
naire was highest in patients receiving MST with autologous 
reconstruction and slightly decreased with BCS, followed by 
MST with implant reconstruction, and was the lowest with 
MST only [7, 27]. Han et al. found that QoL and satisfaction 
as measured by EORTC QLQ-C30 & BR23 was higher for 
BCS as compared to MST or reconstructive surgery [28]. 
These studies suggest that current QoL differences found 
are clinically meaningful. It has also been found that utility 
increases by 0.031 if the patient is given a treatment choice 
versus restricting choice to MST alone [29]. Furthermore, 
if poor cosmesis is expected, other treatment alternatives 
are available, namely, neo-adjuvant chemotherapy and onco-
plastic surgery including therapeutic mammoplasty. Utility 
studies are needed regarding these alternatives to enable 
implementation in a treatment decision model. This study 
should be interpreted as preliminary and a first step towards 
a more ideal treatment decision model.
The treatment decision model presented here is currently 
being studied in a randomized controlled trial in patients 
who are candidates for both BCS and MST to study the 
effectiveness in improving cosmetic result and QoL over 
the present situation [30]. Here, TV/BV ratio is measured 
by ultrasound instead of MRI since it is less invasive, widely 
available, and more cost-effective. Validation of the volume 
measurements is currently awaiting publication. There is 
a fair amount of QoL benefit (0.02 per patient) that can 
be expected if more research is performed that decreases 
parameter uncertainty as shown by our value of information 
analysis. Currently, we are measuring utilities in a larger 
study population for all health states to reduce uncertainty 
and improve the decision model.
Conclusions
A common goal in breast cancer surgery including breast 
reconstruction is to pursue shared treatment decision mak-
ing, which is currently based on informal assessment by the 
surgeon. We present a preliminary treatment decision model 
as a first step towards a more ideal treatment decision model 
applicable in surgical oncology. This treatment decision 
model can improve shared decision making in breast can-
cer surgery. With individual patient characteristics, namely 
tumor/breast volume ratio and tumor location, an expected 
long-term QoL value is given on a scale between 0 and 1 for 
both treatment options. The patient and surgeon can weigh 
the size of the QoL difference between BCS and MST (with 
or without breast reconstruction) or choose the surgery with 
the highest QoL. BCS results in superior QoL in patients 
with tumors located centrally or in the upper breast quad-
rants with a tumor volume/breast ratio below 15. MST with 
or without reconstruction is recommended for all patients 
with a tumor volume/breast volume ratio above 22 or tumors 
in the lower breast quadrants with a tumor volume/breast 
volume ratio above 4. Considering that the model is popula-
tion-, surgeon-, and panel specific, it is advised to validate 
the model before introducing it in other countries.
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